• 1
    Catalona WJ, Richie JP, Ahmann FR, Hudson MA. Comparison of digital rectal examination and serum prostate specific antigen in the early detection of prostate cancer: results of a multicenter clinical trial of 6630 men. J Urol 1994; 151: 12831290
  • 2
    Cooperberg MR, Broering JM, Kantoff PW, Carroll PR. Contemporary trends in low risk prostate cancer: risk assessment and treatment. J Urol 2007; 178: 1425
  • 3
    Raaphorst GP, Romano SL, Mitchell JB, Bedford JS, Dewey WC. Intrinsic differences in heat and/or x-ray sensitivity of seven mammalian cell lines cultured and treated under identical conditions. Cancer Res 1979; 39: 396401
  • 4
    Han M, Partin AW, Zahurak M et al. Biochemical (prostate-specific antigen) recurrence probability following radical prostatectomy for clinically localized prostate cancer. J Urol 2003; 167: 517532
  • 5
    Hull GW, Rabbani F, Abbas F et al. Cancer control with radical prostatectomy alone in 1000 consecutive patients. J Urol 2002; 167: 528534
  • 6
    Kupelian PA, Klein EA. Radical prostatectomy, external beam radiotherapy <72 Gy, external beam radiotherapy > or = 72 Gy, permanent seed implantation, or combined seeds/external beam radiotherapy for stage T1–T2 prostate cancer. Int J Radiat Oncol Biol Phys 2004; 58: 2533
  • 7
    Thompson I, Thrasher JB, Aus G et al. AUA Prostate Cancer Clinical Guideline Update Panel. Guideline for the management of clinically localized prostate cancer: 2007 update. J Urol 2007; 177: 21062131
  • 8
    Bacon CG, Giovannucci E, Testa M et al. The impact of cancer treatment on quality of life outcomes for patients with localized prostate cancer. J Urol 2001; 166: 18041810
  • 9
    Anandadas CN, Clarke NW, Davidson SE et al. Early prostate cancer – which treatment do men prefer and why? BJU Int 2011; 107: 17621768
  • 10
    Blasko JC, Wallner K, Grimm PD, Ragde H. PSA-based disease control following ultrasound-guided 125J implantation for stage T1/T2 prostatic carcinoma. J Urol 1995; 154: 10961099
  • 11
    Potters L, Klein EA, Kattan MW et al. Monotherapy for stage T1–T2 prostate cancer: radical prostatectomy, external beam radiotherapy, or permanent seed implantation. Radiother Oncol 2004; 71: 2933
  • 12
    Potters L, Morgenstern C, Calugaru E, Jassal A, Presser J, Mullen E. 12-year outcomes following permanent prostate brachytherapy in patients with clinically localized prostate cancer. J Urol 2005; 173: 15621566
  • 13
    Stone NN, Stock RG. Long-term urinary, sexual, and rectal morbidity in patients treated with iodine-125 prostate brachytherapy followed up for a minimum of 5 years. Urology 2007; 69: 338342
  • 14
    Machtens S, Baumann R, Hagemann J et al. Long-term results of interstitial brachytherapy (LDR-brachytherapy) in the treatment of patients with prostate cancer. World J Urol 2006; 24: 289295
  • 15
    Prada PJ, Juan G, González-Suárez H et al. Prostate-specific antigen relapse-free survival and side-effects in 734 patients with up to 10 years of follow-up with localized prostate cancer treated by permanent iodine implants. BJU Int 2010; 106: 3236
  • 16
    Grimm P, Billiet I, Bostwick D et al. Comparative analysis of prostate-specific antigen free survival outcomes for patients with low, intermediate and high risk prostate cancer treatment by radical therapy. Results from the Prostate Cancer Results Study Group. BJU Int 2012; 109: 2229
  • 17
    Duchesne G. Radiation for prostate cancer. Lancet Oncol 2001; 2: 7381
  • 18
    Siegsmund M, Musial A, Weiß J, Alken P. Die LDR-Brachytherapie, eine minimal invasive Alternative in der Therapie des organbegrenzten Prostatakarzinoms. Onkologie 2001; 24: 4650
  • 19
    Ohashi T, Yorozu A, Toya K et al. Rectal morbidity following I-125 prostate brachytherapy in relation to dosimetry. Jpn J Clin Oncol 2007; 37: 121126
  • 20
    Emara AM, Chadwick E, Nobes JP, Abdelbaky AM, Laing RW, Langley SE. Long-term toxicity and quality of life up to 10 years after low-dose rate brachytherapy for prostate cancer. BJU Int 2012; 109: 9941000
  • 21
    Zelefsky MJ, Yamada Y, Cohen GN et al. Five-year outcome of intraoperative conformal permanent I-125 interstitial implantation for patients with clinically localized prostate cancer. Int J Radiat Oncol Biol Phys 2007; 67: 6570
  • 22
    Guedea F, Aguilo F, Polo A, Langley S, Laing R, Henderson A. Early biochemical outcomes following permanent interstitial brachytherapy as monotherapy in 1050 patients with clinical T1–T2 prostate cancer. Radiother Oncol 2006; 80: 5761
  • 23
    D'Souza WD, Thames HD, Kuban DA. Dose–volume conundrum for response of prostate cancer to brachytherapy: summary dosimetric measures and their relationship to tumor control probability. Int J Radiat Oncol Biol Phys 2004; 58: 15401548
  • 24
    Nath R, Anderson LL, Luxton G. Dosimetry of interstitial brachytherapy sources: recommandations of the AAPM Radiation Therapy Committee Task Group o.43. American Association of Physicists in Medicine. Med Phys 1995; 22: 209234
  • 25
    Nag S, Beyer D, Friedland J, Grimm P, Nath R. American Brachytherapy Society (ABS) recommendations for transperineal permanent brachytherapy of prostate cancer. Int J Radiat Oncol Biol Phys 1999; 44: 789799
  • 26
    Stock RG, Stone NN, Tabert A, Iannuzzi C, De Wyngaert JK. A dose–response study for I-125 prostate implants. Int J Radiat Oncol Biol Phys 1998; 41: 101108
  • 27
    Potters L, Cao Y, Calugaru E, Torre T, Fearn P, Wang XH. A comprehensive review of CT-based dosimetry parameters and biochemical control in patients treated with permanent prostate brachytherapy. Int J Radiat Oncol Biol Phys 2001; 50: 605614
  • 28
    Stock RG, Kao J, Stone NN. Penile erectile function after permanent radioactive seed implantation for treatment of prostate cancer. J Urol 2001; 165: 436439
  • 29
    Stock RG, Stone NN, Dahlal M, Lo YC. What is the optimal dose for 125I prostate implant? A dose–response analysis of biochemical control, post-treatment prostate biopsies, and long-term urinary symptoms. Brachytherapy 2002; 1: 8389
  • 30
    Barry MJ, Fowler FJ, O'Leary MP et al. The American Urological Association symptom index for benign prostate hyperplasia. J Urol 1992; 148: 15491557
  • 31
    Terk MD, Stock RG, Stone NN. Identification of patients at increased risk for prolonged urinary retention following radioactive seed implantation of the prostate. J Urol 1998; 160: 13791382
  • 32
    Allen Z, Merrick GS, Butler WM et al. Detailed urethral dosimetry in the evaluation of prostate brachytherapy-related urinary morbidity. Int J Radiat Oncol Biol Phys 2005; 4: 981987
  • 33
    Mallick S, Azzouzi R, Cormier L, Peiffert D, Mangin PH. Urinary morbidity after 125I brachytherapy of the prostate. BJU Int 2003; 92: 555558
  • 34
    Thomas C, Keyes M, Liu M, Moravan V. Segmental urethral dosimetry and urinary toxicity in patients with and without symptoms before permanent prostate brachytherapy. Int J Radiat Oncol Biol Phys 2008; 72: 447455
  • 35
    Murakami N, Itami J, Marino H, Nakagawa K. Urethral dose and increment of International Prostate Symptom Score (IPSS) in transperineal permanent interstitial implant (TPI) of prostate cancer. Strahlenther Onkol 2008; 184: 515519
  • 36
    Neill M, Studer G, Le L et al. The nature and extent of urinary morbidity in relation to prostate brachytherapy urethral dosimetry. Brachytherapy 2007; 6: 173179
  • 37
    Cesaretti JA, Stone NN, Stock RG. Urinary symptom flare following I-125 prostate brachytherapy. Int J Radiat Oncol Biol Phys 2003; 56: 10851092
  • 38
    Ash D, Bottomley D, Al-Qaisieh B, Carey B. A prospective analysis of long-term quality of life after permanent I-125 brachytherapy for localised prostate cancer. Radiother Oncol 2007; 84: 135139
  • 39
    Keyes M, Miller S, Moravan V et al. Predictive factors for acute and late urinary toxicity after permanent prostate brachytherapy: long-term outcome in 712 consecutive patients. Int J Radiat Oncol Biol Phys 2009; 73: 10231032
  • 40
    Robinson JW, Moritz S, Fung T. Meta-analysis of rates of erectile function after treatment of localised prostate carcinoma. Int J Radiat Oncol Biol Phys 2002; 54: 10631068
  • 41
    Merrick GS, Butler WM, Galbreath RW. Erectile function after permanent prostate brachytherapy. Int J Radiat Oncol Biol Phys 2002; 52: 893902
  • 42
    Zelefsky MJ, Eid JF. Elucidating the etiology of erectile dysfunction after definitive therapy for prostate cancer. Int J Radiat Oncol Biol Phys 1998; 40: 129133
  • 43
    Bittner N, Merrick GS, Galbreath RW et al. Erectile dysfunction is predictive of all-cause mortality in patients with prostate cancer treated with permanent interstitial brachytherapy. BJU Int 2012; 109: 220225
  • 44
    Carrier S, Hricak H, Lee S et al. Radiation-induced decrease in nitric oxide synthase-containing nerves in the rat penis. Radiology 1995; 195: 955959
  • 45
    Merrick GS, Butler WM, Galbreath RW. Erectile function after permanent prostate brachytherapy. Int J Radiat Oncol Biol Phys 2005; 62: 437447
  • 46
    McDonald AG, Keys M, Kruk A. Predictive factors for erectile dysfunction in men with prostate cancer after brachytherapy: is dose to the penile bulb important? Int J Radiat Oncol Biol Phys 2005; 63: 155163
  • 47
    Solan AN, Cesaretti JA, Stone NN, Stock RG. There is no correlation between erectile dysfunction and dose to penile bulb and neurovascular bundles following real-time low-dose-rate prostate brachytherapy. Int J Radiat Oncol Biol Phys 2009; 73: 14681474